Delanerolle G, Zeng Y, Shi JQ, Yeng X, Goodison W, Shetty A, Shetty S, Haque N, Elliot K, Ranaweera S, Ramakrishnan R, Raymont V, Rathod S, Phiri P. Mental health impact of the Middle East respiratory syndrome, SARS, and COVID-19: A comparative systematic review and meta-analysis. World J Psychiatry 2022; 12(5): 739-765 [PMID: 35663292 DOI: 10.5498/wjp.v12.i5.739]
Corresponding Author of This Article
Peter Phiri, BSc, PhD, RN, Academic Fellow, Department of Research and Innovation, Southern Health NHS Foundation Trust, Clinical Trials Facility, Moorgreen Hospital Botley Road, West End, Southampton SO30 3JB, United Kingdom. peter.phiri@southernhealth.nhs.uk
Research Domain of This Article
Psychiatry
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Non-infected HCWs in SARS outbreak region with high exposure risk vs low exposure risk
Not specified
3
Table 3 Pooled prevalence and confidence interval of anxiety across Middle East respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus-2
Anxiety
Prevalence (%)
95%CI
Heterogeneity I2 (%)
MERS
17.35
8.36-36.02
95.62
SARS-CoV-2
21.48
18.68-24.71
99.76
SARS-CoV
25.20
18.41-34.5
93.47
Table 4 Pooled prevalence and confidence interval of depression across three diseases
Depression
Prevalence (%)
95%CI
Heterogeneity I2 (%)
MERS
33.65
22.02-51.42
69.86
SARS-CoV-2
27.64
24.59-31.06
99.69
SARS-CoV
23.10
18.14-29.4
95.03
Table 5 Pooled prevalence and confidence interval of post-traumatic stress disorder across three diseases
PTSD
Prevalence (%)
95%CI
Heterogeneity I2 (%)
MERS
35.97
29.6-43.72
75.2
SARS-CoV-2
25.03
18.15-34.51
99.58
SARS-CoV
18.20
14.94-22.18
91.37
Table 6 Subgroup analysis on Middle East respiratory syndrome data based on different age groups
Subgroup-age
MERS
Prevalence (%)
95%CI
Heterogeneity I2 (%)
Anxiety
10-19
-
-
-
20-29
-
-
-
30-39
-
-
-
40-49
18.51
8.11-42.23
96.43
50-59
-
-
-
Depression
20-29
-
-
-
30-39
-
-
-
40-49
38.45
25.81-57.26
60.55
50-59
-
-
-
PTSD
20-29
49.70
38.2-64.67
0
30-39
19.32
14.82-25.18
0
40-49
26.69
13.21-53.91
80.63
50-59
-
-
-
60-69
17.87
12.4-25.74
0
Table 7 Subgroup analysis on severe acute respiratory syndrome coronavirus-2 data based on different age groups
Subgroup-age
SARS-CoV-2
Prevalence (%)
95%CI
Heterogeneity I2 (%)
Anxiety
10-19
34.40
33.17-35.68
0
20-29
25.70
19.38-34.08
99.25
30-39
22.86
17.86-29.26
99.64
40-49
15.59
9.65-25.17
99.66
50-59
20.13
10.43-38.84
99.42
60-69
7.75
0.79-76.29
99.47
Depression
10-19
43.91
42.12-45.77
0
20-29
31.03
24.04-40.04
99.12
30-39
30.4
25.15-36.74
99.48
40-49
20.0
13.26-30.18
99.4
50-59
19.98
15.84-25.19
92.68
60-69
4.93
3.45-7.05
90.00
PTSD
20-29
32.40
6.54-160.49
98.29
30-39
21.96
12.77-37.78
99.33
40-49
27.72
19.88-38.66
97.59
50-59
5.38
3.76-7.69
0
60-69
-
-
-
Table 8 Subgroup analysis on severe acute respiratory syndrome coronavirus data based on different age groups
Subgroup-age
SARS-CoV
Prevalence (%)
95%CI
Heterogeneity I2 (%)
Anxiety
10-19
-
-
-
20-29
-
-
-
30-39
24.60
13.29-45.55
85.81
40-49
15.63
10.97-22.26
60.57
50-59
51.62
38.53-69.16
0
Depression
20-29
-
-
-
30-39
27.47
16.09-46.9
89.58
40-49
20.30
13.36-30.85
81.57
50-59
22.49
14.8-34.17
0
60-69
25.85
17.69-37.75
0
PTSD
20-29
24.43
15.53-38.44
72.18
30-39
32.13
23.1-44.68
89.33
40-49
11.68
8.45-16.15
86.20
50-59
67.80
43.57-100
0
60-69
7.54
2.64-21.54
53.28
Table 9 Subgroup analysis on Middle East respiratory syndrome data based on different type of people
Subgroup-occupation
MERS
Prevalence (%)
95%CI
Heterogeneity I2 (%)
Anxiety
General Public
6.04
2.86-12.79
93.9
HCW
-
-
-
Patient
33.95
20.65-55.82
68.57
Depression
General Public
40.70
18.89-87.71
0
HCW
20.52
11.81-35.67
41.71
Patient
41.69
23.73-73.22
71.77
PTSD
General Public
19.02
14.01-25.81
0
HCW
49.87
45.09-55.16
0
Patient
37.70
27.47-51.74
0
Table 10 Subgroup analysis on severe acute respiratory syndrome coronavirus-2 data based on different type of people
Subgroup-occupation
SARS-CoV-2
Prevalence (%)
95%CI
Heterogeneity I2 (%)
Anxiety
General Public
21.18
17.88-25.09
99.82
HCW
22.35
17.42-28.66
99.36
Patient
-
-
-
Depression
General Public
27.6
23.36-32.24
99.8
HCW
27.71
23.22-33.08
98.79
Patient
-
-
-
PTSD
General Public
24.83
14.97-41.18
99.67
HCW
25.16
16.62-38.08
99.33
Patient
-
-
-
Table 11 Subgroup analysis on studies under severe acute respiratory syndrome coronavirus data based on different type of people
Subgroup-occupation
SARS-CoV
Prevalence (%)
95%CI
Heterogeneity I2 (%)
Anxiety
General Public
26.19
11.93-57.48
98.22
HCW
98.44
22.67-427.49
0
Patient
24.21
17.34-33.79
85.16
Depression
General Public
23.31
14.64-37.11
97.97
HCW
25.42
13.74-47.03
90.29
Patient
21.96
16.86-28.6
78.1
PTSD
General Public
18.36
13.59-24.81
81.69
HCW
16.97
12.28-23.45
91.8
Patient
19.80
14.28-27.46
90.44
Table 12 Sensitivity analysis for anxiety and depression studies under severe acute respiratory syndrome coronavirus-2
Exposure
Outcome
Prevalence with 95%CI (before)
Prevalence with 95%CI (after)
P value
(g)
SARS-CoV-2
Anxiety
21.48 (18.66-24.71)
25.82 (23.98-27.8)
< 0.05
(h)
SARS-CoV-2
Depression
27.64 (24.59-31.06)
29.3 (26.98-31.81)
> 0.05
Citation: Delanerolle G, Zeng Y, Shi JQ, Yeng X, Goodison W, Shetty A, Shetty S, Haque N, Elliot K, Ranaweera S, Ramakrishnan R, Raymont V, Rathod S, Phiri P. Mental health impact of the Middle East respiratory syndrome, SARS, and COVID-19: A comparative systematic review and meta-analysis. World J Psychiatry 2022; 12(5): 739-765